{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T13:14:51Z","timestamp":1769692491404,"version":"3.49.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,5,2]],"date-time":"2019-05-02T00:00:00Z","timestamp":1556755200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1007\/s12094-019-02124-9","type":"journal-article","created":{"date-parts":[[2019,5,2]],"date-time":"2019-05-02T11:03:55Z","timestamp":1556795035000},"page":"130-136","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Survival outcomes in patients aged 75\u00a0years and over with peritoneal colorectal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC): multicenter study of the Spanish Group of Peritoneal Cancer Surgery (GECOP)"],"prefix":"10.1007","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6703-6372","authenticated-orcid":false,"given":"P. A.","family":"Cascales-Campos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"L\u00f3pez-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Torres-Melero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Arjona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F. C.","family":"Mu\u00f1oz-Casares","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Barrios","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Morales","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Bretcha-Boix","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Gonz\u00e1lez-Bay\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Gonz\u00e1lez-Moreno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Gil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,5,2]]},"reference":[{"key":"2124_CR1","doi-asserted-by":"publisher","first-page":"3737","DOI":"10.1200\/JCO.2003.04.187","volume":"21","author":"VJ Verwaal","year":"2003","unstructured":"Verwaal VJ, van Ruth S, de Bree E, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol. 2003;21:3737\u201343.","journal-title":"J Clin Oncol"},{"key":"2124_CR2","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1245\/s10434-008-9966-2","volume":"15","author":"VJ Verwaal","year":"2008","unstructured":"Verwaal VJ, Bruin S, Boot H, et al. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol. 2008;15:2426\u201332.","journal-title":"Ann Surg Oncol"},{"key":"2124_CR3","doi-asserted-by":"publisher","first-page":"4195","DOI":"10.1245\/s10434-014-3798-z","volume":"21","author":"J Esquivel","year":"2014","unstructured":"Esquivel J, Lowy AM, Markman M, et al. The American Society of Peritoneal Surface Malignancies (ASPSM) Multiinstitution evaluation of the peritoneal surface disease severity score (PSDSS) in 1,013 patients with colorectal cancer with peritoneal carcinomatosis. Ann Surg Oncol. 2014;21:4195\u2013201.","journal-title":"Ann Surg Oncol"},{"key":"2124_CR4","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1002\/jso.23728","volume":"110","author":"A Prada-Villaverde","year":"2014","unstructured":"Prada-Villaverde A, Esquivel J, Lowy AM, et al. The American Society of Peritoneal Surface Malignancies evaluation of HIPEC with Mitomycin C versus Oxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgery. J Surg Oncol. 2014;110:779\u201385.","journal-title":"J Surg Oncol"},{"key":"2124_CR5","doi-asserted-by":"publisher","first-page":"3284","DOI":"10.1200\/JCO.2004.10.012","volume":"22","author":"O Glehen","year":"2004","unstructured":"Glehen O, Kwiatkowski F, Sugarbaker PH, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol. 2004;22:3284\u201392.","journal-title":"J Clin Oncol"},{"key":"2124_CR6","first-page":"3019","volume":"23","author":"E de Bree","year":"2003","unstructured":"de Bree E, Romanos J, Michalakis J, et al. Intraoperative hyperthermic intraperitoneal chemotherapy with docetaxel as second-line treatment for peritoneal carcinomatosis of gynaecological origin. Anticancer Res. 2003;23:3019\u201327.","journal-title":"Anticancer Res"},{"key":"2124_CR7","first-page":"987475","volume":"2014","author":"JD Spiliotis","year":"2014","unstructured":"Spiliotis JD, Halkia E, Boumis VA, et al. Cytoreductive surgery and HIPEC for peritoneal carcinomatosis in the elderly. Int J Surg Oncol. 2014;2014:987475.","journal-title":"Int J Surg Oncol."},{"key":"2124_CR8","first-page":"687","volume":"25","author":"A Macr\u00ec","year":"2011","unstructured":"Macr\u00ec A, Saladino E, Trimarchi G, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy in elderly patients. Vivo. 2011;25:687\u201390.","journal-title":"Vivo."},{"key":"2124_CR9","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1002\/jso.22019","volume":"105","author":"YL Klaver","year":"2012","unstructured":"Klaver YL, Chua TC, de Hingh IH, et al. Outcomes of elderly patients undergoing cytoreductive surgery and perioperative intraperitoneal chemotherapy for colorectal cancer peritoneal carcinomatosis. J Surg Oncol. 2012;105:113\u20138.","journal-title":"J Surg Oncol"},{"key":"2124_CR10","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.suronc.2013.06.001","volume":"22","author":"P Tabrizian","year":"2013","unstructured":"Tabrizian P, Jibara G, Shrager B, et al. Outcomes for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the elderly. Surg Oncol. 2013;22:184\u20139.","journal-title":"Surg Oncol"},{"key":"2124_CR11","doi-asserted-by":"publisher","first-page":"3497","DOI":"10.1245\/s10434-013-3053-z","volume":"20","author":"KI Votanopoulos","year":"2013","unstructured":"Votanopoulos KI, Newman NA, Russell G, et al. Outcomes of Cytoreductive Surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients older than 70\u00a0years; survival benefit at considerable morbidity and mortality. Ann Surg Oncol. 2013;20:3497\u2013503.","journal-title":"Ann Surg Oncol"},{"key":"2124_CR12","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.suronc.2016.09.002","volume":"25","author":"V L\u00f3pez-L\u00f3pez","year":"2016","unstructured":"L\u00f3pez-L\u00f3pez V, Cascales-Campos PA, Schneider MA, Gil J, Gil E, Gomez-Hidalgo NR, Parrilla P. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in\u00a0elderly\u00a0patients. A systematic literature review. Surg Oncol. 2016;25:378\u201384.","journal-title":"Surg Oncol."},{"key":"2124_CR13","first-page":"1","volume":"39","author":"F Quenet","year":"2018","unstructured":"Quenet F, et al. A UNICANCER phase III trial of hyperthermic intra-peritoneal chemotherapy (HIPEC) for colorectal peritoneal carcinomatosis (PC): PRODIGE 7. J Clin Oncol. 2018;39:1.","journal-title":"J Clin Oncol"},{"key":"2124_CR14","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1200\/JCO.2004.05.113","volume":"22","author":"C Tournigand","year":"2004","unstructured":"Tournigand C, Andr\u00e9 T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004;22:229\u201337.","journal-title":"J Clin Oncol"},{"key":"2124_CR15","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1200\/JCO.2010.33.5091","volume":"29","author":"E van Cutsem","year":"2011","unstructured":"van Cutsem E, K\u00f6hne C, L\u00e1ng I, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol. 2011;29:2011\u20139.","journal-title":"J Clin Oncol"},{"key":"2124_CR16","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1200\/JCO.2007.14.9930","volume":"26","author":"LB Saltz","year":"2008","unstructured":"Saltz LB, Clarke S, D\u00edaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008;26:2013\u20139.","journal-title":"J Clin Oncol"},{"key":"2124_CR17","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ejca.2018.12.019","volume":"109","author":"DP Modest","year":"2019","unstructured":"Modest DP, Pant S, Sartore-Bianchi A. Treatment sequencing in metastatic\u00a0colorectal\u00a0cancer. Eur J Cancer. 2019;109:70\u201383.","journal-title":"Eur J Cancer"},{"key":"2124_CR18","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/S1470-2045(14)70330-4","volume":"15","author":"V Heinemann","year":"2014","unstructured":"Heinemann V, von Weikersthal LF, Decker T, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomized, open-label, phase 3 trial. Lancet Oncol. 2014;15:1065\u201375.","journal-title":"Lancet Oncol."},{"key":"2124_CR19","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1002\/jso.10255","volume":"83","author":"M Deraco","year":"2003","unstructured":"Deraco M, Casali P, Inglese MG, et al. Peritoneal mesothelioma treated by induction chemotherapy, cytoreductive surgery, and intraperitoneal hyperthermic perfusion. J Surg Oncol. 2003;83:147\u201353.","journal-title":"J Surg Oncol"},{"key":"2124_CR20","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1245\/ASO.2004.09.008","volume":"11","author":"D Elias","year":"2004","unstructured":"Elias D, Delperro JR, Sideris L, et al. Treatment of peritoneal carcinomatosis from colorectal cancer: impact of complete cytoreductive surgery and difficulties in conducting randomized trials. Ann Surg Oncol. 2004;11:518\u201321.","journal-title":"Ann Surg Oncol"},{"key":"2124_CR21","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1038\/sj.bjc.6601586","volume":"90","author":"H Mahteme","year":"2004","unstructured":"Mahteme H, Hansson J, Berglund A, et al. Improved survival in patients with peritoneal metastases from colorectal cancer: a preliminary study. Br J Cancer. 2004;90:403\u20137.","journal-title":"Br J Cancer"},{"key":"2124_CR22","doi-asserted-by":"publisher","first-page":"4011","DOI":"10.1200\/JCO.2006.07.1142","volume":"24","author":"TD Yan","year":"2006","unstructured":"Yan TD, Black D, Savady R, Sugarbaker PH. Systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal carcinoma. J Clin Oncol. 2006;24:4011\u20139.","journal-title":"J Clin Oncol"},{"key":"2124_CR23","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ygyno.2007.03.019","volume":"106","author":"JH Bae","year":"2007","unstructured":"Bae JH, Lee JM, Ryu KS, et al. Treatment of ovarian cancer with paclitaxel-or carboplatin-based intraperitoneal hyperthermic chemotherapy during secondary surgery. Gynecol Oncol. 2007;106:193\u2013200.","journal-title":"Gynecol Oncol"},{"key":"2124_CR24","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1016\/j.ejso.2009.03.004","volume":"35","author":"MJ Pavlov","year":"2009","unstructured":"Pavlov MJ, Kovacevic PA, Ceranic MS, et al. Cytoreductive surgery and modified heated intraoperative intraperitoneal chemotherapy (HIPEC) for advanced and recurrent ovarian cancer\u201412-year single center experience. Eur J Surg Oncol. 2009;35:1186\u201391.","journal-title":"Eur J Surg Oncol"},{"key":"2124_CR25","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1097\/SLA.0b013e3181b5ae43","volume":"251","author":"TC Chua","year":"2010","unstructured":"Chua TC, Saxena A, Schellekens JF, et al. Morbidity and mortality outcomes of cytoreductive surgery and perioperative intraperitoneal chemotherapy at a single tertiary institution: towards a new perspective of this treatment. Ann Surg. 2010;251:101\u20136.","journal-title":"Ann Surg"},{"key":"2124_CR26","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.suronc.2016.03.007","volume":"25","author":"PA Cascales-Campos","year":"2016","unstructured":"Cascales-Campos PA, L\u00f3pez-L\u00f3pez V, Mu\u00f1oz-Casares FC, Feliciangeli E, Torres Melero J, Barrios P, Morales R, Ramos I, Ortega G, Camps B, Gonz\u00e1lez-Bay\u00f3n L, Bretcha-Boix P, Farr\u00e9-Alegre J, Gonz\u00e1lez-Moreno S, Gil J. Morbidity and mortality outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients\u00a0aged\u00a075\u00a0years and over: Spanish Group of Peritoneal Cancer Surgery (GECOP) multicenter study. Surg Oncol. 2016;25:111\u20136.","journal-title":"Surg Oncol"},{"key":"2124_CR27","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1097\/SLA.0b013e31825b35d5","volume":"256","author":"AG Acheson","year":"2012","unstructured":"Acheson AG, Brookes MJ, Spahn DR. Effects of allogeneic red blood cell transfusions on clinical outcomes in patients undergoing colorectal cancer surgery: a systematic review and meta-analysis. Ann Surg. 2012;256:235\u201344.","journal-title":"Ann Surg"},{"key":"2124_CR28","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1097\/01.TA.0000022460.21283.53","volume":"54","author":"GE Hill","year":"2003","unstructured":"Hill GE, Frawley WH, Griffith KE, et al. Allogeneic blood transfusion increases the risk of postoperative bacterial infection: a meta-analysis. J Trauma. 2003;54:908\u201314.","journal-title":"J Trauma"},{"key":"2124_CR29","doi-asserted-by":"publisher","first-page":"2656","DOI":"10.1245\/s10434-014-4297-y","volume":"22","author":"GA Simkens","year":"2015","unstructured":"Simkens GA, van Oudheusden TR, Luyer MD, et al. Serious postoperative complications affect early recurrence after cytoreductive surgery and HIPEC for colorectal peritoneal carcinomatosis. Ann Surg Oncol. 2015;22:2656\u201362.","journal-title":"Ann Surg Oncol"},{"key":"2124_CR30","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1097\/SLA.0b013e3182128929","volume":"253","author":"A Mirnezami","year":"2011","unstructured":"Mirnezami A, Mirnezami R, Chandrakumaran K, et al. Increased local recurrence and reduced survival from colorectal cancer following anastomotic leak: systematic review and meta-analysis. Ann Surg. 2011;253:890\u20139.","journal-title":"Ann Surg"},{"key":"2124_CR31","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1038\/nature07205","volume":"454","author":"A Mantovani","year":"2008","unstructured":"Mantovani A, Allavena P, Sica A, et al. Cancer-related inflammation. Nature. 2008;454:436\u201344.","journal-title":"Nature"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-019-02124-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12094-019-02124-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-019-02124-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,30]],"date-time":"2020-04-30T23:09:30Z","timestamp":1588288170000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12094-019-02124-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,2]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["2124"],"URL":"https:\/\/doi.org\/10.1007\/s12094-019-02124-9","relation":{},"ISSN":["1699-048X","1699-3055"],"issn-type":[{"value":"1699-048X","type":"print"},{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,2]]},"assertion":[{"value":"26 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The current study has been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All patients signed informed consent forms and were treated according to clinical protocol approved by the Institutional Review Board of each center.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}